BR100 Increased By (0.82%)
BR30 Increased By (0.87%)
KSE100 Increased By (0.79%)
KSE30 Increased By (0.85%)
AGHA 6.45 Increased By ▲ 0.07 (1.1%)
BECO 4.38 Increased By ▲ 0.03 (0.69%)
BML 62.83 Increased By ▲ 0.28 (0.45%)
BOP 31.42 Increased By ▲ 0.03 (0.1%)
CNERGY 11.81 Increased By ▲ 0.08 (0.68%)
CSIL 5.80 Decreased By ▼ -0.11 (-1.86%)
FCCL 61.80 Increased By ▲ 0.09 (0.15%)
FFL 14.98 Increased By ▲ 0.19 (1.28%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.81 Decreased By ▼ -0.09 (-1.53%)
LOTCHEM 24.80 Increased By ▲ 0.11 (0.45%)
MLCF 105.70 Increased By ▲ 1.77 (1.7%)
NBP 174.68 Increased By ▲ 1.36 (0.78%)
NCPL 52.02 Increased By ▲ 0.19 (0.37%)
NPL 54.47 Increased By ▲ 0.44 (0.81%)
OGDC 318.70 Increased By ▲ 2.83 (0.9%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.72 Increased By ▲ 0.14 (0.39%)
PIBTL 14.15 Increased By ▲ 0.49 (3.59%)
PPL 229.03 Increased By ▲ 2.96 (1.31%)
PRL 81.76 Increased By ▲ 1.48 (1.84%)
PTC 46.87 Increased By ▲ 0.23 (0.49%)
SSGC 23.97 Increased By ▲ 0.15 (0.63%)
TBL 9.30 Increased By ▲ 0.06 (0.65%)
TELE 7.70 Increased By ▲ 0.15 (1.99%)
TPL 24.80 Increased By ▲ 0.26 (1.06%)
TPLP 12.90 Decreased By ▼ -0.09 (-0.69%)
TREET 25.94 Decreased By ▼ -0.04 (-0.15%)
TRG 53.71 Increased By ▲ 0.38 (0.71%)
Markets

Sanofi raises sales outlook on Dupixent strength in boost for new CEO

  • Sanofi on Thursday raised its full-year sales forecast on the back of strong demand for blockbuster asthma drug Dupixent
Published Updated
By

LONDON: Sanofi on Thursday raised its full-year sales forecast on the back of strong demand for blockbuster asthma drug Dupixent, with investors focused on new CEO Belen Garijo’s first address for her plans to revive the French company’s drug development engine.

Garijo has taken the helm at a time when the drugmaker is under investor scrutiny to secure a growth plan beyond the company’s star drug Dupixent.

In her first weeks on the job, Garijo has overhauled her executive team, appointed a new R&D chief, and dropped plans to seek approval for its experimental eczema drug, amlitelimab. Sanofi now expects sales to grow by 10% at constant exchange

rates in 2026, compared to its previous forecast of high-single-digit percentage growth. It continues to expect business operating income to grow slightly faster than sales.

The company posted second-quarter business operating income of €3.29 billion ($3.77 billion), compared with analyst average estimates of €2.96 billion, according to data compiled by Vara Research provided by the company. Quarterly revenue came in at €11.60 billion, versus estimates of €10.85 billion.

Comments

200 characters remaining